Key Takeaways AbbVie expects 2026 oncology sales of $6.5 billion, down from 2025 due to lower Imbruvica pricing.Newer drugs like Epkinly, Elahere and Emrelis are driving growth, offsetting Imbruvica declines.AbbVie is advancing ADCs and pipeline candidates to strengthen its oncology portfolio.AbbVie (ABBV) has built a significant presence in the oncology space. While the majority of the revenues are generated from blood cancer drugs Imbruvica and Venclexta, the company has diversified its offerings with new ...

Continue Reading First-time CoolSculpting users can learn how to claim $400 off their treatment. IRVINE, Calif., March 31, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting®, the treatment doctors use most for nonsurgical fat reduction.1 Spring is often thought of as a transformative season, making the return of CoolMonth this April a perfect opportunity to reprioritize aesthetic goals. In fact, 50% o ...

AbbVie to Host First-Quarter 2026 Earnings Conference Call Accessibility StatementSkip Navigation NORTH CHICAGO, Ill., March 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first- quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be avail ...

The Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) has a very simple strategy. It tracks an index that aims to hold the top 100 high-yielding dividend stocks. That index reshuffles its holdings once a year to ensure it contains only the best of the best. The fund recently completed its annual reconstitution. One of the more notable changes was an increase in its allocation to high-yielding dividend stocks in the healthcare sector. Here's a closer look at some of the fund's recent changes. Will AI create t ...

Core Insights - The Growth Stock Forum focuses on identifying attractive growth stocks, particularly in the biotech sector, emphasizing risk/reward situations [1] - The biotech Top Picks of the forum achieved a remarkable increase of 137.6% last year, with a compound annual growth rate (CAGR) of 35.3% since 2017 [1] - The core portfolio, LTGP, has also demonstrated strong performance with a CAGR of 23.2% as of March 20, 2026 [1]

Core Insights - AbbVie is set to present new research at the 2026 American Academy of Dermatology (AAD) Annual Meeting, showcasing advancements in standards of care for immune-mediated skin diseases [1][2] Group 1: Research Highlights - AbbVie will present 24 abstracts, including a late-breaking presentation, emphasizing its leadership in immune-mediated skin diseases [2] - The clinical evidence demonstrates durable treatment responses, long-term safety, and quality of life improvements across various dermatologic diseases [2][3] - Key findings include the long-term efficacy of risankizumab in maintaining radiographic non-progression in psoriatic arthritis, with 88% of patients showing no progression over five years [5] Group 2: Quality of Life Improvements - Data indicates significant quality of life improvements for patients with atopic dermatitis and psoriasis, with risankizumab showing high efficacy in treating these conditions [4][6] - In the UnlIMMited trial, 72% to 88.9% of patients with genital psoriasis achieved a Dermatology Life Quality Index (DLQI) score of 0 or 1 after 16 weeks of treatment [6] - Real-world evidence from the AD-VISE study shows that 72.3% of patients achieved minimal disease activity with upadacitinib treatment [5][9] Group 3: Investigational Data - Phase 3 data for upadacitinib in treating non-segmental vitiligo and severe alopecia areata will be presented, highlighting its potential efficacy [8][9] - The investigational studies show a greater proportion of patients achieving significant improvements in disease severity compared to placebo [8][9] - Upadacitinib is currently not FDA approved for vitiligo and alopecia areata, indicating ongoing research and development in these areas [8][9]

Core Viewpoint - Seeking dividend income from investments is a smart strategy, and AbbVie is highlighted as a solid dividend-paying stock with a yield significantly above the S&P 500 average [1] Group 1: Dividend Information - AbbVie's last quarterly dividend payment was $1.73 per share, leading to an annual run rate of $6.92 per share [2] - To achieve $10,000 in annual dividend income, an investor would need to purchase 1,445 shares of AbbVie, costing approximately $296,225 at a recent stock price of $205 per share [2] - AbbVie has increased its dividend payout by more than 330% since its spin-off in 2013 and has a history of annual increases for over 25 years when combined with Abbott Labs [4] Group 2: Financial Performance - AbbVie has a market capitalization of $373 billion and a recent stock price range between $205.83 and $211.42 [3][4] - The stock has averaged annual gains of 16.2% over the past decade, with a recent revenue increase of 8.6% despite losing patent protection for its major drug, Humira [5] - AbbVie's forward-looking price-to-earnings (P/E) ratio is 14, slightly above its five-year average of 13, indicating reasonable pricing [5]

Core Insights - Eli Lilly (LLY) and AbbVie (ABBV) are prominent U.S. drugmakers with strong market positions and diverse therapeutic portfolios, including immunology, oncology, and neuroscience [1][2] - Lilly's success is driven by its GLP-1 drugs, Mounjaro and Zepbound, which accounted for over 50% of its total revenues in 2025 [3][4] - AbbVie has successfully transitioned from the loss of exclusivity of Humira by launching new immunology drugs, Skyrizi and Rinvoq, which generated $26 billion in sales in 2025 [12][13] Summary of Eli Lilly - Mounjaro and Zepbound generated combined sales of $36.5 billion in 2025, representing around 56% of total revenues [4][10] - Lilly's new drugs and obesity pipeline, including orforglipron, are expected to drive sales growth in 2026 [5][10] - The company is investing in a broad obesity pipeline with various oral and injectable medications [6][7] - Despite strong growth prospects, Lilly faces challenges such as declining product prices and rising competition in the GLP-1 market [11] Summary of AbbVie - AbbVie has effectively managed the impact of Humira's loss of exclusivity by launching Skyrizi and Rinvoq, which are expected to generate over $31 billion in sales in 2026 [12][13] - The neuroscience portfolio contributed to a 20% increase in sales, reaching $10.8 billion in 2025 [14] - AbbVie has been active in acquisitions to enhance its early-stage pipeline, investing over $5 billion in 2025 [15] - The company anticipates a revenue growth of approximately 9.5% in 2026, supported by strong performances from its new drugs [27][28] Financial Estimates and Valuation - The Zacks Consensus Estimate for Lilly's 2026 sales and EPS implies increases of 25.7% and 41.1%, respectively [17] - AbbVie's 2026 sales and EPS estimates suggest growth of 9.6% and 45.6%, respectively [19] - Lilly's stock has risen 9.2% over the past year, while AbbVie's stock has increased by 2.0% [22] - AbbVie appears more attractive from a valuation perspective, with a forward P/E ratio of 13.75 compared to Lilly's 25.12 [22][24]

Group 1: Company Overview - AbbVie (NYSE:ABBV) is an American pharmaceutical company based in Illinois, developing, manufacturing, and selling drugs for a wide range of medical issues, including treatments for various cancers and inflammatory diseases, as well as skincare products [4] Group 2: Recent Developments - AbbVie expanded its psychiatry pipeline by acquiring the psychedelic compound bretisilocin from Gilgamesh Pharmaceuticals for $1.2 billion in 2025, which is a Phase 2 psychedelic drug candidate aimed at treating major depressive disorder [1] - AbbVie announced topline results from a Phase 1 study of ABBV-295, an amylin analog drug candidate targeting obesity, which were deemed competitive in the amylin class by William Blair [3] Group 3: Analyst Ratings - Guggenheim reiterated its Buy rating on AbbVie stock with a target price of $242, citing confidence in the growth outlook for Skyrizi and noting that AbbVie's overall business remains robust despite competition [2] - William Blair reaffirmed its Outperform rating on AbbVie stock, highlighting the potential of the company's obesity drug candidate following positive Phase 1 study results [3]

Group 1: AbbVie - AbbVie is recognized as a reliable dividend raiser and is classified as a Dividend King, having raised its dividend annually for at least 50 years, although it is a spinoff from Abbott Laboratories [2] - Concerns arose earlier this decade regarding AbbVie losing patent exclusivity on its blockbuster drug Humira, but the company proactively strengthened its pipeline and made strategic acquisitions, introducing next-generation treatments Skyrizi and Rinvoq [3] - In the fourth quarter, Skyrizi and Rinvoq generated nearly $7.4 billion in net revenue, accounting for 44% of AbbVie's total revenue for that period [4] - AbbVie's neuroscience portfolio, led by the antipsychotic treatment Vraylar, also showed strong performance with a year-over-year revenue increase of 18%, totaling just under $3 billion [4] - The company's free cash flow is robust, supporting its long-standing dividend policy with a quarterly payout of $1.73 per share, yielding 3.4% [5] Group 2: Bristol Myers Squibb - Bristol Myers Squibb faces similar patent expiration challenges as AbbVie, particularly with its cancer drugs Revlimid and Opdivo [6] - The company is focusing on innovation within its oncology lineup, which is part of its growth portfolio, resulting in a 16% year-over-year revenue increase in the fourth quarter, reaching almost $7.4 billion [6]